Olink AB (publ) (OLK) Revenue & Revenue Breakdown
Olink AB (publ) Revenue Highlights
Latest Revenue (Y)
$169.91M
Latest Revenue (Q)
$28.59M
Main Geography (Y)
UNITED STATES
Olink AB (publ) Revenue by Period
Olink AB (publ) Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $169.91M | 21.49% |
2022-12-31 | $139.85M | 47.25% |
2021-12-31 | $94.97M | 75.66% |
2020-12-31 | $54.07M | 29.68% |
2019-12-31 | $41.69M | - |
Olink AB (publ) Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-03-31 | $28.59M | -58.73% |
2023-12-31 | $69.27M | 56.89% |
2023-09-30 | $44.15M | 49.99% |
2023-06-30 | $29.44M | 7.21% |
2023-03-31 | $27.46M | -52.57% |
2022-12-31 | $57.88M | 82.19% |
2022-09-30 | $31.77M | 15.48% |
2022-06-30 | $27.51M | 21.33% |
2022-03-31 | $22.68M | -48.09% |
2021-12-31 | $43.68M | 118.70% |
2021-09-30 | $19.97M | 12.92% |
2021-06-30 | $17.69M | 29.79% |
2021-03-31 | $13.63M | -49.87% |
2020-12-31 | $27.19M | 147.23% |
2020-09-30 | $11.00M | 39.49% |
2020-06-30 | $7.88M | -1.43% |
2020-03-31 | $8.00M | - |
Olink AB (publ) Revenue Breakdown
Olink AB (publ) Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|
CHINA | $9.65M | $9.48M | - |
UNITED STATES | $73.64M | - | - |
SWEDEN | $15.43M | $13.42M | - |
Rest of world | $5.05M | $11.78M | $596.00K |
JAPAN | $7.00M | $10.03M | - |
Americas | $5.12M | $133.03M | $27.11M |
EMEA (excluding Sweden) | $53.71M | $101.96M | $26.61M |
Sweden | - | - | $3.15M |
Japan | - | - | $2.60M |
China | - | - | $148.00K |
Olink AB (publ) Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
QGEN | Qiagen | $1.97B | $458.80M |
NEOG | Neogen | $924.22M | $228.81M |
GTH | Genetron | $650.71M | $201.32M |
BNR | Burning Rock Biotech | $537.43M | $125.62M |
LMDX | LumiraDx | $254.48M | $21.00M |
CSTL | Castle Biosciences | $219.79M | $87.00M |
OLK | Olink AB (publ) | $169.91M | $28.59M |
FONR | FONAR | $98.65M | $25.72M |
STIM | Neuronetics | $71.35M | $16.45M |
XGN | Exagen | $52.55M | $15.06M |
ACRS | Aclaris Therapeutics | $31.25M | $2.40M |
PMD | Psychemedics | $22.10M | $5.36M |
DRIO | DarioHealth | $20.35M | $6.25M |
SERA | Sera Prognostics | $306.00K | - |
OLK Revenue FAQ
What is Olink AB (publ)’s yearly revenue?
Olink AB (publ)'s yearly revenue for 2023 was $169.91M, representing an increase of 21.49% compared to 2022. The company's yearly revenue for 2022 was $139.85M, representing an increase of 47.25% compared to 2021. OLK's yearly revenue for 2021 was $94.97M, representing an increase of 75.66% compared to 2020.
What is Olink AB (publ)’s quarterly revenue?
Olink AB (publ)'s quarterly revenue for Q1 2024 was $28.59M, a -58.73% decrease from the previous quarter (Q4 2023), and a 4.12% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $69.27M, a 56.89% increase from the previous quarter (Q3 2023), and a 19.67% increase year-over-year (Q4 2022). OLK's quarterly revenue for Q3 2023 was $44.15M, a 49.99% increase from the previous quarter (Q2 2023), and a 38.97% increase year-over-year (Q3 2022).
What is Olink AB (publ)’s revenue growth rate?
Olink AB (publ)'s revenue growth rate for the last 3 years (2021-2023) was 78.90%, and for the last 5 years (2019-2023) was 307.52%.